APL-130277
Total Payments
$9.9M
Transactions
1,514
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $2.3M | 519 | 1 |
| 2018 | $7.2M | 953 | 0 |
| 2017 | $399,172 | 42 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.9M | 1,509 | 99.6% |
| Consulting Fee | $33,515 | 4 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,250 | 1 | 0.1% |
Payments by Type
Research
$9.9M
1,509 transactions
General
$38,765
5 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease | Sunovion Pharmaceuticals Inc. | $5.9M | 0 |
| Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease | Sunovion Pharmaceuticals Inc. | $3.1M | 0 |
| A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes | Sunovion Pharmaceuticals Inc. | $594,530 | 0 |
| A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes | Sunovion Pharmaceuticals Inc. | $224,217 | 0 |
| IIG_APL-130277 | Sunovion Pharmaceuticals Inc. | $100,052 | 0 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $9.9M
- Total Doctors 4
- Transactions 1,514
About APL-130277
APL-130277 is a drug associated with $9.9M in payments to 4 healthcare providers, recorded across 1,514 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2017 to 2019. In 2019, $2.3M was paid across 519 transactions to 1 doctors.
The most common payment nature for APL-130277 is "Unspecified" ($9.9M, 99.6% of total).
APL-130277 is associated with 5 research studies, including "An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease" ($5.9M).